Page 5 - Aytu Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – – Stockholders are encouraged to vote, no matter how many or how few shares they own – – Vote TODAY by telephone, online at www.proxyvote.com, or by mailing proxy card – – MacKenzie Partners, the Company’s proxy solicitor, is available to answer any questions and help stockholders vote their shares – DALLAS and FORT WORTH, Texas...

Aytu BioScience, Inc.: Aytu BioScience to Present at Upcoming March Investor Conferences ENGLEWOOD, CO / ACCESSWIRE / February 24, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, today announced that Josh Disbrow, Chairman and Chief Executive Officer will present at three upcoming investor conferences in March: Cowen 41 st Annual Healthcare Conference: A live virtual presentation will occur on Wednesday, March 3, 2021 at 10:20 a.m. ET. H.C. Wainwright Global Life Sciences Conferenc...

A comprehensive new market research report on  GABA Receptor Agonist market published by DBMR gives details about historic data, present market trends, future product environment, marketing strategies, Strategic recommendations, Competitive Intelligence, emerging trends and the technical progress in the related industry. This intelligence report includes investigations based on Current scenarios, Historical records, and Future predictions. The report contains different market related to market size, trends, segmentation, revenue, production, CAGR, Consumption, gross margin, diagrams, graphs...

(2) Live Conference Call and Webcast at 4:30 PM ET ENGLEWOOD, CO / ACCESSWIRE / February 4, 2021 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal second quarter ended December 31, 2020 on February 11, 2021, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy. Conference Call Information 201-689-8584 (interna...

Health your username February 4, 2021 A Neos Therapeutics, Inc. shareholder has filed suit against the company and its board of directors for violations of the Securities Exchange Act of 1934, arising from the board’s attempt to sell the company to Aytu BioScience, Inc. through its wholly-owned subsidiary Neutron Acquisition Sub, Inc (together, Aytu). The Southern District of New York complaint, filed on Wednesday, contends that the defendants filed a materially incomplete and misleading registration statement that must be amended in order for shareholders to make an informed decision about...